CN114174281B - 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途 - Google Patents
细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途 Download PDFInfo
- Publication number
- CN114174281B CN114174281B CN202080050815.4A CN202080050815A CN114174281B CN 114174281 B CN114174281 B CN 114174281B CN 202080050815 A CN202080050815 A CN 202080050815A CN 114174281 B CN114174281 B CN 114174281B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- bispecific compound
- cancer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882958P | 2019-08-05 | 2019-08-05 | |
| US62/882,958 | 2019-08-05 | ||
| PCT/US2020/044815 WO2021026109A1 (en) | 2019-08-05 | 2020-08-04 | Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114174281A CN114174281A (zh) | 2022-03-11 |
| CN114174281B true CN114174281B (zh) | 2025-02-07 |
Family
ID=74503218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080050815.4A Active CN114174281B (zh) | 2019-08-05 | 2020-08-04 | 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12491251B2 (https=) |
| EP (1) | EP4010336B1 (https=) |
| JP (1) | JP7636388B2 (https=) |
| CN (1) | CN114174281B (https=) |
| AU (1) | AU2020324408B2 (https=) |
| CA (1) | CA3149374A1 (https=) |
| ES (1) | ES3031581T3 (https=) |
| WO (1) | WO2021026109A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| WO2021133601A1 (en) * | 2019-12-24 | 2021-07-01 | Dana-Farber Cancer Institute, Inc. | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| CN113234081A (zh) * | 2021-05-27 | 2021-08-10 | 东南大学 | 一种吡咯并吡唑衍生物与dmpeda做脲的制备方法 |
| US20240343732A1 (en) * | 2021-05-28 | 2024-10-17 | Qurient Co., Ltd. | Compounds for degradation of cyclin-dependent kinase 7(cdk7) |
| CN116396295A (zh) * | 2023-04-04 | 2023-07-07 | 合肥工业大学 | 一种基于protac的plk1降解剂的合成方法 |
| WO2025252190A1 (en) * | 2024-06-07 | 2025-12-11 | Cullgen Inc. | Targeted degraders of werner syndrome recq helicase |
| CN119119072B (zh) * | 2024-08-23 | 2025-10-03 | 武汉大学 | 一种用于检测和降解ERα的诊疗一体化ERαPROTACs化合物及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108366992A (zh) * | 2015-11-02 | 2018-08-03 | 耶鲁大学 | 蛋白水解靶向嵌合体化合物及其制备和应用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1320531T3 (da) | 2000-08-10 | 2011-01-03 | Pfizer Italia Srl | Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2013070688A1 (en) * | 2011-11-11 | 2013-05-16 | Yale University | Reprogramming urokinase into an antibody-recruiting anticancer agent |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| EP3270917A4 (en) * | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| MX394157B (es) * | 2015-06-15 | 2025-03-24 | Ube Corp | Derivado de dihidropirrolopirazol sustituido. |
| CA3018429A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| CN109516989B (zh) | 2017-09-17 | 2021-12-31 | 上海美志医药科技有限公司 | 一类抑制并降解cdk的化合物 |
-
2020
- 2020-08-04 ES ES20849357T patent/ES3031581T3/es active Active
- 2020-08-04 CN CN202080050815.4A patent/CN114174281B/zh active Active
- 2020-08-04 US US17/631,774 patent/US12491251B2/en active Active
- 2020-08-04 AU AU2020324408A patent/AU2020324408B2/en active Active
- 2020-08-04 WO PCT/US2020/044815 patent/WO2021026109A1/en not_active Ceased
- 2020-08-04 CA CA3149374A patent/CA3149374A1/en active Pending
- 2020-08-04 JP JP2022506574A patent/JP7636388B2/ja active Active
- 2020-08-04 EP EP20849357.7A patent/EP4010336B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108366992A (zh) * | 2015-11-02 | 2018-08-03 | 耶鲁大学 | 蛋白水解靶向嵌合体化合物及其制备和应用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7636388B2 (ja) | 2025-02-26 |
| EP4010336B1 (en) | 2025-04-02 |
| US20220280649A1 (en) | 2022-09-08 |
| AU2020324408B2 (en) | 2026-03-12 |
| EP4010336A4 (en) | 2023-08-23 |
| CA3149374A1 (en) | 2021-02-11 |
| ES3031581T3 (en) | 2025-07-09 |
| WO2021026109A1 (en) | 2021-02-11 |
| JP2022543231A (ja) | 2022-10-11 |
| EP4010336A1 (en) | 2022-06-15 |
| AU2020324408A1 (en) | 2021-12-16 |
| US12491251B2 (en) | 2025-12-09 |
| CN114174281A (zh) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114174281B (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途 | |
| US12110292B2 (en) | Ligands to cereblon (CRBN) | |
| CN113896685B (zh) | 吲哚胺-2,3-双加氧酶(ido)抑制剂 | |
| CN108472295B (zh) | 二价溴结构域抑制剂及其用途 | |
| EP4034132B1 (en) | Erk5 degraders as therapeutics in cancer and inflammatory diseases | |
| US11905285B2 (en) | Inhibitors of plasma kallikrein and uses thereof | |
| HK1224140A1 (zh) | 转录因子抑制剂及其用途 | |
| HK1225383A1 (zh) | 二氮杂环庚烷衍生物及其用途 | |
| CN113164475A (zh) | Dyrk1a的大环抑制剂 | |
| CN105939607A (zh) | 二氢蝶啶酮衍生物及其用途 | |
| JP7626721B2 (ja) | 小分子標的ブロモ／アセチルタンパク質およびその使用 | |
| HK1256417A1 (zh) | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 | |
| CN113557017A (zh) | 细胞周期蛋白依赖性激酶7的抑制剂及其用途 | |
| JP2017520586A (ja) | ハリコンドリン類似体の合成およびその使用 | |
| KR20220098732A (ko) | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 | |
| WO2024148274A1 (en) | Complement inhibition | |
| HK1228196A1 (en) | Dihydropteridinone derivatives and uses thereof | |
| HK40000485A (en) | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |